Green­Light's mR­NA vac­cine nabs tri­al OK; Ra­tio reels in ra­dio­ther­a­py funds

Green­Light Bio­sciences will test its Covid-19 mR­NA vac­cine in Rwan­da, the biotech said.

The RNA R&D and man­u­fac­tur­ing com­pa­ny said the Rwan­da FDA gave the go-ahead for a Phase I/II study test­ing the vac­cine as a boost­er for peo­ple who have al­ready been vac­ci­nat­ed against the pan­dem­ic virus.

“It is es­pe­cial­ly im­por­tant to de­vel­op vac­cines that are glob­al­ly af­ford­able and scal­able. Green­Light’s ef­forts to ini­ti­ate this clin­i­cal study in Rwan­da show the com­pa­ny’s com­mit­ment to sup­port Africa’s goal of af­ford­able vac­cine self-suf­fi­cien­cy,” said Mark Dy­bul, who chairs Green­Light’s sci­en­tif­ic ad­vi­so­ry board for hu­man health, in a press re­lease.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.